Accuray Inc
ARAY
View Detailed Chart
1.670USD
-0.070-4.02%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
188.12MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.02%
5 Days
+6.37%
1 Month
+10.60%
6 Months
-10.70%
Year to Date
-15.66%
1 Year
-12.11%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
5.500
Target Price
+216.09%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
Undervalued
The company’s latest PE is -107.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 68.05M shares, decreasing 6.33% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.37M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
Ticker SymbolARAY
CompanyAccuray Inc
CEOMs. Suzanne C. Winter
Websitehttps://www.accuray.com/
Related Instruments
-0.32%
+0.66%
-0.41%
-1.01%
-0.46%
-0.19%
-0.04%
-1.02%
+1.23%
-0.64%
-1.80%
-0.27%
-2.84%
-1.19%
-0.78%
-0.30%
+0.98%
-0.72%
-1.25%
-3.23%
